Dupilumab for the treatment of atopic dermatitis in transplant patients: Two case reports and literature review

Abstract

Dupilumab for the treatment of atopic dermatitis in transplant patients: Two case reports and literature review Dear Editor, Dupilumab, a monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis (AD), has a good safety profile. 1

Vitiligo during dupilumab therapy

“… 1 It is approved for the treatment of moderate-to-severe atopic dermatitis (AD), asthma, and chronic rhinosinusitis with nasal polyps, as well as recently for prurigo nodularis, showing efficacy and good long-term safety profile in clinical trials and real-life studies. 2 , 3 , 4 Despite these data, a number of recent publications have reported various adverse events. 2 Injection-site reactions are the most commonly reported adverse events, followed by ophthalmic complications (dry eyes, conjunctivitis, blepharitis, and keratitis), paradoxical head and neck erythema (“dupilumab red face”), onset of psoriatic lesions, progression of cutaneous T-cell lymphoma, alopecia areata, and arthritis.…”